Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx (LUNG) has reported Cash & Equivalents for 7 consecutive years, with $69.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 1.63% year-over-year to $69.8 million in Q4 2025; TTM through Dec 2025 was $69.8 million, a 1.63% decrease from a year earlier, with the FY2025 full-year figure at $69.8 million, down 1.63% from the prior year.
• Cash & Equivalents was $69.8 million for Q4 2025 at Pulmonx, down from $76.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $209.3 million in Q1 2021 and troughed at $63.3 million in Q3 2024.
• A 5-year average of $108.2 million and a median of $98.3 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 1188.61% in 2021 and sank 40.24% in 2022, its largest moves.
• Over 5 years, Cash & Equivalents stood at $148.5 million in 2021, then slumped by 31.48% to $101.7 million in 2022, then decreased by 17.88% to $83.5 million in 2023, then dropped by 15.13% to $70.9 million in 2024, then declined by 1.63% to $69.8 million in 2025.
• The last three Cash & Equivalents figures came in at $69.8 million (Q4 2025), $76.5 million (Q3 2025), and $75.5 million (Q2 2025), per Business Quant data.